PMA SEEKING FASTER REIMBURSEMENT SETTING FROM JAPANESE
PMA SEEKING FASTER REIMBURSEMENT SETTING FROM JAPANESE at a Sept. 30 meeting with Japan's Chuikyo, the Ministry of Health and Welfare's advisory council for setting reimbursement levels, Abbott Labs' Regulatory/Scientific Affairs official Robert Olson told a Sept. 25 session of the Regulatory Affairs Professionals Society (RAPS) annual meeting. Noting that "reimbursement is really the whole key to getting sales in Japan," Olson said representatives of the Pharmaceutical Manufacturers Association and the U.S. Chamber of Commerce will meet with the Chuikyo in Tokyo. "We are continually trying to push for faster reimbursement" after a product has been approved for Japanese marketing, he explained. Pharmaceutical pricing is also expected to be discussed at length. The meeting reportedly was organized after Japan's Chuikyo informed the U.S. Embassy in Tokyo that it needed advice on medical product reimbursements.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth